Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (569)	11/5/2002 12:13:32 PM
From: scaram(o)uche	Respond to of 724

apart from the fact that it's in DGI's best interest that Novo maintain dominance in diabetes...... nope.

To: richardred who wrote (569)	1/24/2003 12:31:23 PM
From: richardred	Respond to of 724

Hopefully Novo will give DGI continued funding in insulin research. On Thursday, Novartis AG (NVS) pulled out of the clinical trials on an anti- diabetic insulin sensitizer coded DRF-4158 by Dr. Reddy's, which had licensed the compound to the Swiss drug company in May 2001 for $55 million, including royalties and milestone payments. So far, Dr. Reddy's has received only $5 million for the compound. And late July last year, Novo Nordisk AS (NVO) of Denmark decided to stop further development of another insulin drug of Dr. Reddy's, coded DRF-2725, after test animals developed tumors on being administered the experimental drug. Most low-cost Indian drugmakers are now focusing on new molecules and licensing them out on lucrative terms to major foreign companies at various stages of the drug's development. But analysts such as Bhat believe it will be difficult for Dr. Reddy's to forge such alliances. Furthermore, of the three anti-diabetic experimental drugs sold by Dr. Reddy's, two have been rejected. The fate of one more, coded DRF- 2593 and licensed to Novo Nordisk, isn't known. The only other insulin drug in the pipeline, coded DRF-NPPC, isn't a direct replacement of DRF-4158 rejected by Novartis Thursday. Strong Global Alliance Against Dr Reddy's Finding a quick replacement for the rejected compound to keep its research alliance with Novartis alive is only one of the major problems facing Dr. Reddy's. Its insulin research faces a tough challenge from the alliance between U.S.- based Eli Lilly and Co. (LLY) and Amylin Pharmaceuticals Inc. (AMLN) focusing on anti-diabetes drugs